Cutting edge discovery and development targeting Parkinson's disease
About our model
MIDBRAIN ORGANOIDS
Organoids contain a high amount of dopaminergic neurons but also other types of neurons (GABAergic, glutamatergic) and astrocytes.
FURTHER DEVELOPMENT
They can be enriched with endothelial cells and microglia.
PHENOTYPING AND DRUG DISCOVERY
Midbrain organoids from PD patients show dopaminergic neuron impairment. We specialize in compound screening and drug discovery.
Our project pipeline
Our services include project design and different phases of experimental procedures and analysis.
They are fully customizable and adapted to your project needs.
Organoid generation
Project design, choice of cellular target, and culture timelines (organoid maturation status). Generation of midbrain organoids.
Experimental analysis
Wet lab experiments based on the project needs (neuronal phenotypes, autophagy, mitochondrial phenotypes, neuroinflammation, etc ).
Compound treatment
Project design: choice of drug concentrations and treatment duration. Treatment of midbrain organoids with drug candidates.
Data analysis
Complete analysis of the observed results accompanied by a discussion.
Image analysis and artificial intelligence
We use a set of computational AI tools to perform deep phenotyping of our models to better detect cellular defects and their rescue following compound treatments. For more details, see our publication.
IP
Monzel A.S., Bolognin S., Schwamborn J.C. (2016) Means and methods for generating midbrain organoids: US11976296B2
